CorMedix: Challenging Long-Term Risk-Reward, Maintain Sell

CorMedix surged on strong DefenCath sales and a Melinta acquisition. I maintain a Sell rating on CRMD stock, citing ...

CEE: Low P/E For Overlooked But Developed Markets In Europe

The Central and Eastern Europe Fund, Inc. remains attractive with low portfolio P/E of 8.58x and 12% earnings yield. Read why ...